Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Microcap Potential Homeruns--Credible, and Reporting -- Ignore unavailable to you. Want to Upgrade?

To: NAG1 who wrote (685)	1/10/2011 5:35:46 PM
From: thomas a. burke	Read Replies (1) \| Respond to of 1056

Thanks Neal. Just ran through it and am very pleased with the projections. However, I was most pleased with the following statements found at the bottom of page 3: ================================= This new glucose strip will have several key and positive economic features after its imminent introduction into the marketplace. Although the diagnostic product uses its own proprietary methodologies, its performance characteristics are almost identical to those of the leading brand, including accuracy (which is paramount) and time-to-result. Demand will be recurring because testing must be administered multiple times daily by the diabetic user and the strips are not re-usable. Its projected market price will be 50% below that of the current market-share leader’s product. This diagnostic will provide a superb value proposition for major retailers (chain pharmacies, omni-store retailers, etc.) In our opinion this new Distribution Agreement and a recently signed agreement with the world’s largest retailer should prove to be epochal events in the corporate history and growth of ISCR.